Regulatory Tracker
FDA warning letters, enforcement actions, court rulings, and vendor status changes across the peptide and GLP-1 market — logged as they are published, each with a primary source. See also GLP-1 medications, the provider comparison, and what these actions mean for compounded semaglutide.
- Warning letters
- Enforcement actions
- Vendor status changes
-
FDA declares the semaglutide shortage resolved, starting the clock on compounding
Read more: FDA declares the semaglutide shortage resolved, starting the clock on compoundingThe FDA determined that the shortage of semaglutide injection products, in place since 2022, was resolved, after confirming with the manufacturer that stated availability and manufacturing capacity could meet present and projected national demand. Because the legal basis for compounding these products rested on their presence on the shortage list, the announcement set two deadlines:…